amedisys is a leading provider of healthcare in the home with a vision of becoming the premiere solution for patients across the country to age in place. from home health to hospice to personal care, amedisys team members provide quality, clinically-distinctive care to more than 376,000 patients every year. every life is precious and tells an incredible story, and we celebrate that each day by honoring our patients with genuine, personal attention. everything we do, from the boardroom to our nationwide network of care centers, is centered on the best care possible for those who have entrusted us with their well-being and comfort. we work closely with doctors and other healthcare providers to coordinate services, and every patient has an individual plan of care that meets their specific needs. amedisys recognizes that nothing we do is possible without our incredible team. for all employees, whether they’re on the front lines delivering direct care or supporting our clinical team, this i
Company profile
Ticker
AMED
Exchange
Website
CEO
Paul Kusserow
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
COMPASSIONATE CARE HOSPICE GROUP, INC. • COMPASSIONATE CARE HOSPICE OF CENTRAL FLORIDA, INC. • COMPASSIONATE CARE HOSPICE OF LAKE AND SUMTER, INC. • COMPASSIONATE CARE HOSPICE OF MIAMI DADE AND THE FLORIDA KEYS, INC. • GUARDIAN HEALTH CARE, INC. • GUARDIAN HEALTH CARE GROUP, INC. • GUARDIAN HEALTH CARE HOLDINGS, INC. • HEALTH PRIORITY HOME CARE, INC. • HI-TECH CARE, INC. • HOMECARE PREFERRED CHOICE, INC. ...
IRS number
113131700
AMED stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
19 Mar 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Amedisys Reports Fourth Quarter and Year-end 2023 Financial Results
21 Feb 24
10-Q
2023 Q3
Quarterly report
25 Oct 23
8-K
Amedisys Reports Third Quarter 2023 Financial Results
24 Oct 23
8-K
Submission of Matters to a Vote of Security Holders
8 Sep 23
DEFA14A
Additional proxy soliciting materials
1 Sep 23
8-K
Other Events
1 Sep 23
8-K
Departure of Directors or Certain Officers
30 Aug 23
DEFM14A
Proxy related to merger
10 Aug 23
Transcripts
AMED
Earnings call transcript
2022 Q4
16 Feb 23
AMED
Earnings call transcript
2022 Q3
27 Oct 22
AMED
Earnings call transcript
2022 Q2
28 Jul 22
AMED
Earnings call transcript
2022 Q1
28 Apr 22
AMED
Earnings call transcript
2021 Q4
25 Feb 22
AMED
Earnings call transcript
2021 Q3
3 Nov 21
AMED
Earnings call transcript
2021 Q2
8 Aug 21
AMED
Earnings call transcript
2021 Q2
5 Aug 21
AMED
Earnings call transcript
2021 Q1
2 May 21
AMED
Earnings call transcript
2020 Q4
26 Feb 21
Latest ownership filings
4
Nick Muscato
21 Feb 24
4
Adam Y Holton
21 Feb 24
4
Scott G Ginn
21 Feb 24
4
Michael Paul North
21 Feb 24
4
Richard M Ashworth
21 Feb 24
4
Denise M. Bohnert
21 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
Flynn James E
12 Feb 24
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
8 Feb 24
SC 13G/A
BlackRock Inc.
24 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 94.02 mm | 94.02 mm | 94.02 mm | 94.02 mm | 94.02 mm | 94.02 mm |
Cash burn (monthly) | 5.72 mm | (no burn) | (no burn) | (no burn) | 3.28 mm | (no burn) |
Cash used (since last report) | 38.04 mm | n/a | n/a | n/a | 21.84 mm | n/a |
Cash remaining | 55.97 mm | n/a | n/a | n/a | 72.18 mm | n/a |
Runway (months of cash) | 9.8 | n/a | n/a | n/a | 22.0 | n/a |
Institutional ownership, Q3 2023
94.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 284 |
Opened positions | 36 |
Closed positions | 51 |
Increased positions | 89 |
Reduced positions | 114 |
13F shares | Current |
---|---|
Total value | 2.66 tn |
Total shares | 30.87 mm |
Total puts | 615.90 k |
Total calls | 56.80 k |
Total put/call ratio | 10.8 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 3.24 mm | $302.72 bn |
BLK Blackrock | 2.95 mm | $275.96 bn |
Flynn James E | 1.79 mm | $137.49 mm |
Pentwater Capital Management | 1.14 mm | $106.85 bn |
Alpine Associates Management | 1.03 mm | $96.53 bn |
Wellington Management | 981.05 k | $91.63 bn |
MKFCF Mackenzie Financial | 941.06 k | $88.36 bn |
STT State Street | 927.08 k | $86.59 bn |
Westchester Capital Management | 850.39 k | $79.43 bn |
Millennium Management | 806.77 k | $75.35 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Feb 24 | Bohnert Denise M. | Common Stock | Payment of exercise | Dispose F | No | No | 93.69 | 1,415 | 132.57 k | 15,843 |
20 Feb 24 | Nick Muscato | Common Stock | Payment of exercise | Dispose F | No | No | 93.69 | 327 | 30.64 k | 20,516 |
20 Feb 24 | Ginn Scott G | Common Stock | Payment of exercise | Dispose F | No | No | 93.69 | 3,218 | 301.49 k | 83,177 |
16 Feb 24 | Ashworth Richard M | Common Stock | Grant | Acquire A | No | No | 0 | 55,175 | 0.00 | 112,688 |
16 Feb 24 | Bohnert Denise M. | Common Stock | Grant | Acquire A | No | No | 0 | 5,518 | 0.00 | 17,258 |
16 Feb 24 | Nick Muscato | Common Stock | Grant | Acquire A | No | No | 0 | 5,518 | 0.00 | 20,843 |
16 Feb 24 | Adam Y Holton | Common Stock | Grant | Acquire A | No | No | 0 | 5,518 | 0.00 | 10,863 |
16 Feb 24 | Ginn Scott G | Common Stock | Grant | Acquire A | No | No | 0 | 16,553 | 0.00 | 86,395 |
News
Raymond James Maintains Market Perform on Amedisysto Market Perform
26 Mar 24
RBC Capital Maintains Outperform on Amedisys, Raises Price Target to $100
25 Mar 24
Amedisys Q4 2023 Adj EPS $0.94 Misses $1.03 Estimate, Sales $570.80M Beat $567.71M Estimate
21 Feb 24
Amedisys Offers Molecular Testing For Rapid And Accurate Infection Diagnosis In Collaboration With Patient Choice Laboratories
8 Feb 24